New Study Says Stretta is Valuable GERD Treatment

A newly published peer-reviewed paper concludes that Mederi Therapeutics’ Stretta therapy is a safe, effective and durable treatment for gastro esophageal reflux disease (GERD).


You may be surprised to learn that GERD is the most frequent outpatient diagnosis in the United States. Although most patients are treated with proton pump inhibitors (PPIs), up to 40 percent of patients have incomplete control of reflux symptoms on PPIs. What sufferers are then faced with as a veritable arms race of surgical and non surgical options.

One such is Stretta, manufactured by Mederi Therapeutics, a non-surgical treatment that involves the delivery of radiofrequency energy to the muscle of the lower esophageal sphincter and gastric cardia. Stretta doesn’t alter the anatomy or implant any foreign material and does not preclude further steps with more invasive procedures if indicated. According to the author, Stretta is the least expensive alternative to medical therapy.

The paper states that Stretta addresses a significant unmet need where patients receive inadequate control from PPI therapy and find surgery an undesirable option. The paper was authored by George Triadafilopoulos, MD, Clinical Professor of Medicine at Stanford University School of Medicine and was published in the World Journal of Gastroenterology.

It also states that Stretta treatment does not result in any tissue destruction, nor create scar tissue. Symptom control is consistent among Stretta patients who were previously PPI dependent or poorly controlled by PPI. Functional improvements occur post-Stretta, including improved acid sensitivity and decreased tissue compliance

The paper concludes that Stretta is “exceedingly safe, durable and reproducible”

Physician comments 

Dr. Triadafilopoulos states, “Today, more than ever, clinicians will benefit from the addition of Stretta to the treatment armamentarium for their GERD patients.” The comprehensive review examines the more than 35 studies published on the procedure, including a recent 10-year follow up study, and concludes that Stretta is a highly valuable middle treatment option between PPI’s and surgery.

Source: Mederi Therapeutics, PR Newswire

Share your thoughts

Your email address will not be published. Required fields are marked *